Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 26414-26424
DOI: 10.1021/acs.jmedchem.6c02236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.10.2026. Verfasst von Quan Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Med…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Receptors, Neurotensin, Antigens, Surface. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Jiangsu Provincial Medical Key Discipline Laboratory, Jiangsu Commission of Health, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA) is a key biomarker for prostate cancer (PCa), while neurotensin receptor 1 (NTSR1) is positive in PSMA-negative PCa lesions. For comprehensive diagnosis and therapy of PCa, we synthesized dual-targeted PSNT-AB (combining PSMA-targeted EuK, NTSR1-targeted NT-20.3, albumin-binding 4-p-tolylbutyric acid and DOTA moieties) and prepared [68Ga]Ga/[177Lu]Lu-PSNT-AB. [68Ga]Ga-PSNT-AB possessed high affinity for PSMA-positive LNCaP and moderate affinity for NTSR1-positive PC-3 cells. Probes accumulated time-dependently in relevant cells, and [177Lu]Lu-PSNT-AB exerted potent cytotoxicity. Pharmacokinetics revealed prolonged blood half-lives for both probes. PET imaging revealed persistent [68Ga]Ga-PSNT-AB uptake in LNCaP, 22Rv1 and PC-3 tumors (10.29 ± 0.25% ID/g, 6.61 ± 0.30% ID/g, 3.74 ± 0.12% ID/g at 3 h post-injection). SPECT/CT showed sustained [177Lu]Lu-PSNT-AB retention in LNCaP tumors for at least 24 h. These results demonstrated that [68Ga]Ga/[177Lu]Lu-PSNT-AB are promising dual-targeted probes for PCa diagnosis and therapy, offering a potential strategy for comprehensive and effective precision management of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi214063, China.
- Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing211166, China.
ORCID-Profile: Qingzhu Liu, Jianguo Lin
Förderung
- Jiangsu Provincial Medical Key Discipline Laboratory
- Jiangsu Commission of Health
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Xie, Q., Peng, Y., Liu, Q., Qin, J., Li, J., Li, X., Qiu, L., & Lin, J. (2026). Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics. Journal of Medicinal Chemistry, 69(21), 26414-26424. https://doi.org/10.1021/acs.jmedchem.6c02236
Vancouver
Xie Q, Peng Y, Liu Q, Qin J, Li J, Li X, et al. Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics. Journal of Medicinal Chemistry. 2026;69(21):26414-26424. doi:10.1021/acs.jmedchem.6c02236
BibTeX
@article{Xie2026,
author = {Xie, Quan and Peng, Ying and Liu, Qingzhu and Qin, Jiawen and Li, Jing and Li, Xinru and Qiu, Ling and Lin, Jianguo},
title = {Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {26414--26424},
doi = {10.1021/acs.jmedchem.6c02236}
}
EUVIMED